Biophan's Biomedical Breakthroughs to Gain Exposure with European Institutional Investors at BioScience Economy Conference
|Company CEO to Provide Detailed Report on Biophan Solutions and Strategic Goals at Leading European Investor Forums|
“Biophan has received strong support from investors throughout Europe, and we recognize the importance of increasing visibility and understanding of Biophan's technology and business strategy among institutional investors in these markets”
Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, announced that CEO Michael Weiner has been invited to present the Company's advanced solutions, which address a range of multi-billion-dollar biomedical markets, at a leading European investor community conference, the annual Bioscience Economy Conference to be held on October 19 in Lausanne and Geneva, Switzerland, and on October 20 in Milan, Italy.
"Biophan has received strong support from investors throughout Europe, and we recognize the importance of increasing visibility and understanding of Biophan's technology and business strategy among institutional investors in these markets," said Mr. Weiner, who will make the upcoming presentation. "The Bioscience Economy Conference in Switzerland and Italy will provide an excellent opportunity to further expand our Company's already notable recognition among institutional investors in Europe. These investors and other financial professionals have shown keen interest in our Company, and have enthusiastically supported our business potential as a leading provider of advanced solutions for the global healthcare industry."
Biophan is a biomedical development leader with a strong intellectual property portfolio of 156 U.S. patents, licenses, or applications and 46 international applications. The Company is focused on commercializing its technology via licensing agreements with large manufacturers. The Company's diverse range of advanced solutions enable safer and/or more effective implanted medical devices and other medical tools that may be used with Magnetic Resonance Imaging (MRI) environments. Biophan recently launched an initiative to expand its presence in cardiovascular devices, one of the fastest-growing segments of the biomedical industry, with an expected value of nearly $28 billion before the end of this decade.
About the Bioscience Economy Conference(TM)
Capitalife organizes the Bioscience Economy Conference(TM), a yearly series of conferences in Italy and Switzerland committed to bridge the industrial and financial communities and expand their reciprocal knowledge. Capitalife provides a link and offers tailored high quality services to the life sciences industry and institutional investors; focuses on European markets such as Italy, Switzerland, U.K., and France; and offers to institutional investors independent analyses and due diligence. For more information, please visit http://www.capitalife.com/bioscience_conference.html.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.